Metagenomics

Trace Genomics and Taurus Agricultural Marketing partner to bring next-generation soil testing to Canada

Retrieved on: 
목요일, 8월 24, 2023
Metagenomics, DNA, Partnership, Canadian Agricultural Safety Association, Genomics, Fertilizer, Agriculture, AB, Consultant, Translation, Chemistry, Soil, Fertility, Nitrogen, Phosphorus, Trace, AMES

AMES, Iowa and CALGARY, AB, Aug. 24, 2023 /PRNewswire/ -- Trace Genomics (Trace), an industry-leading provider of science-validated soil biology insights, and Taurus Agricultural Marketing (Taurus Ag), market-leading distributor of agricultural products in Canada, announced an international partnership today.

Key Points: 
  • AMES, Iowa and CALGARY, AB, Aug. 24, 2023 /PRNewswire/ -- Trace Genomics (Trace), an industry-leading provider of science-validated soil biology insights, and Taurus Agricultural Marketing (Taurus Ag), market-leading distributor of agricultural products in Canada, announced an international partnership today.
  • Trace is revolutionizing agricultural soil testing by providing comprehensive, actionable insights to growers and retailers in the United States, and now, Canada.
  • "Disruptions are rare and take time, but with Trace Genomics' metagenomic approach, we're seeing a transformative shift in agricultural analytics," said Craig Davidson, President, Taurus Agricultural Marketing.
  • "Taurus Ag is a valuable partner for our expansion into Canada," said Justin Miller, Director of Sales at Trace Genomics.

Global Metagenomic Sequencing Market: Key Segments, Growth Trajectories, and More" - ResearchAndMarkets.com

Retrieved on: 
화요일, 8월 22, 2023
Health, Genetics, Other Science, Clinical Trials, Science, Biotechnology, Metagenomics, COVID-19, Clinical metagenomic sequencing, Risk, Drug discovery, Growth, Pharmaceutical industry

The "Metagenomic Sequencing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metagenomic Sequencing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
  • The report presents a comprehensive analysis of the global metagenomic sequencing market, focusing on geographic regions including the USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • It provides insights into the recent past, current, and future trends for metagenomic sequencing, including annual sales data in US$ Thousand for the years 2022 through 2030 and percentage CAGR.
  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.

One Codex and 4bases team up to empower clinicians with solutions for microbiome analysis

Retrieved on: 
목요일, 7월 20, 2023
Metagenomics, Software as a service, Partnership, Genomics, Privacy, Fungus, Patient, Bacteria, Health, Virus, Codex, Medical device, EU

WILMINGTON, Del. and MANNO, Switzerland, July 20, 2023 /PRNewswire-PRWeb/ -- One Codex, a leading provider of cloud-based microbial genomics analysis software, is thrilled to announce a groundbreaking partnership with 4bases. This strategic collaboration brings together One Codex' unmatched sensitivity and specificity for microbial characterization and 4bases' cutting-edge CE-IVD solutions to address demand for integrated, sample-to-report solutions appropriate for clinicians in the EU.

Key Points: 
  • One Codex, a leading provider of cloud-based microbial genomics analysis software and 4bases, a Swiss manufacturer of CE-IVD solutions, partner on sample-to-report solutions for microbiome analysis.
  • and MANNO, Switzerland, July 20, 2023 /PRNewswire-PRWeb/ -- One Codex, a leading provider of cloud-based microbial genomics analysis software, is thrilled to announce a groundbreaking partnership with 4bases.
  • This strategic collaboration brings together One Codex' unmatched sensitivity and specificity for microbial characterization and 4bases' cutting-edge CE-IVD solutions to address demand for integrated, sample-to-report solutions appropriate for clinicians in the EU.
  • "We are excited to join forces with 4bases to offer this end-to-end solution for microbiome analysis in Europe," said Christopher Smith, General Manager at One Codex.

Global Genomics Market Report 2023: Sector is Expected to Reach $411.35 Billion by 2030 at a CAGR of 19.4% - ResearchAndMarkets.com

Retrieved on: 
수요일, 7월 12, 2023
Biotechnology, Health, Genetics, Science, Research, Molecular biology, Co-production (public services), Metagenomics, Sanger, GSA, Academic institution, Budapest Metropolitan University, Genomics, Hospital, Agriculture, Economy, NGS, Medication, Cancer, Union budget of India, RNA, MEA, Medicine, Brain, Thermo Fisher Scientific, USD, Government, Ancestry.com, TGS, Incidence, 2021 Union budget of India, FDI, Ministry of Agriculture, Animal Industry and Fisheries (Uganda), Application, Drug discovery, Plant growth analysis, Scania OmniExpress, Growth, Diagnosis, Massive parallel sequencing, Safety, PCR, Genome, Antibiotics, Vaccine, Purification, Illumina, Sequencing

The global genomics market size was valued at USD 27.81 billion in 2021 and is poised to grow from USD 33.25 billion in 2022 to USD 411.35 billion by 2030, growing at a CAGR of 19.4% in the forecast period (2023-2030).

Key Points: 
  • The global genomics market size was valued at USD 27.81 billion in 2021 and is poised to grow from USD 33.25 billion in 2022 to USD 411.35 billion by 2030, growing at a CAGR of 19.4% in the forecast period (2023-2030).
  • Government funding for genomics efforts has increased as a result of the rising incidence of cancer worldwide.
  • Global Genomics Market is segmented based on Deliverables, Technology, End Use, application, and Region.
  • The growth of Next-Generation Sequencing (NGS), which is increasingly being employed in cancer research, is driving the global genomics market.

Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis

Retrieved on: 
화요일, 6월 20, 2023
Software, Research, General Health, Consumer, Technology, Infectious Diseases, University, Education, Science, Biotechnology, Other Science, Health, Metagenomics, Institute of Biochemistry and Biophysics, Bio, GV, Infection, University of California, San Francisco, Section 32, Encephalitis, DRS, Innovation, Genomics, Cerebrospinal fluid, Fungus, Technology management, Biochemistry, Dicarboxylic acid, Chan Zuckerberg Biohub, Patient, UCSF, Parasitism, Biophysics, OTMA, Diagnosis, Bacteria, Foundation Medicine, Virus, Meningitis, Pharmaceutical industry, Vaccine

The funds will be used to commercialize the company’s mNGS-based infectious disease test – which was developed by world-renowned infectious disease experts at the University of California San Francisco (UCSF) Center for Next-Gen Precision Diagnostics – and advance a pipeline of next-generation tests.

Key Points: 
  • The funds will be used to commercialize the company’s mNGS-based infectious disease test – which was developed by world-renowned infectious disease experts at the University of California San Francisco (UCSF) Center for Next-Gen Precision Diagnostics – and advance a pipeline of next-generation tests.
  • Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti and Matthew Meyerson – world leaders in genomics, metagenomics, and infectious disease.
  • “While genomic testing has been transformative for oncology, rare disease and women’s health, infectious disease has been largely overlooked,” said Brad Murray, co-founder and CEO of Delve.
  • “We firmly believe that mNGS delivers the most conclusive, unbiased and actionable diagnosis of infectious disease,” said Joe DeRisi, Ph.D., Delve Bio co-founder, professor of Biochemistry and Biophysics at UCSF, and president of the Chan Zuckerberg Biohub.

Element Enters the European Genomics Market with New Customers and a Growing Team

Retrieved on: 
월요일, 6월 5, 2023
Metagenomics, European Society of Human Genetics, VIB, Research, Genomics, RNA, Doctor of Philosophy, Organization, Human genetics, Y RNA, SAN, Element, RNA-Seq, Entrepreneurship, Flanders, European Society of Cardiology, Library, Conference, Fine chemical, Nature Biotechnology

Its flexibility enables us to produce high quality data with fast turnaround," said Stefaan Derveaux, manager of the Nucleomics Core at VIB.

Key Points: 
  • Its flexibility enables us to produce high quality data with fast turnaround," said Stefaan Derveaux, manager of the Nucleomics Core at VIB.
  • A year after launching the AVITI System, Element has completed successful installations across the United States, Asia and now Europe.
  • With the establishment of a European entity and a growing sales and support organization, Element can now support a wide variety of applications and research labs across the world.
  • "We look forward to bringing the benefits of AVITI's flexibility, data quality, ease of use, and excellent support team to a growing number of customers in the European market," said Molly He, PhD, Element CEO and Co-Founder.

Metagenomi Presents New Data on Novel Gene Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
금요일, 5월 19, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Metagenomics, Database, DNA, CRISPR, Human genome, Therapy, Gene, PAM, Gene editing, Enzyme, Immunity, Escherichia coli, Genome, Cell, RNA, Hepatocyte, Cloud computing, Poster, Cas9, Annual general meeting, PID, Oral, ABE, Observation, NHP, LNP, Safety, Society, DSM-IV codes, Synthetic natural environment, Vaccine, Antibiotics, Mouse

Metagenomi , a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, presented new data for its gene editing programs during the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting.

Key Points: 
  • Metagenomi , a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, presented new data for its gene editing programs during the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting.
  • The presentations demonstrate enhanced efficiency of Metagenomi’s proprietary type V and type II nucleases, first-in-class CAST systems for large, targeted DNA integration capabilities, and novel base editing systems.
  • In addition, the Company presented proof of concept data in non-human primates, showcasing potential therapeutic translation of Metagenomi’s lead novel nuclease technologies.
  • This provides proof of concept for potential therapeutic application – and a critical advancement for the gene editing field.

Zymo Research launches full-length 16S sequencing service to revolutionize microbiome research

Retrieved on: 
수요일, 5월 17, 2023
Pacific Biosciences, Metagenomics, Partnership, Senior, Abraxis BioScience, NGS, Business, Research, Doctor of Philosophy, Emerging market, Microbiology, Antibiotics

IRVINE, Calif., May 17, 2023 /PRNewswire/ -- Zymo Research , a leading provider of microbiology research tools, has officially launched its Full-Length 16S Sequencing Service, offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis.

Key Points: 
  • IRVINE, Calif., May 17, 2023 /PRNewswire/ -- Zymo Research , a leading provider of microbiology research tools, has officially launched its Full-Length 16S Sequencing Service, offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis.
  • Zymo Research is releasing this new service using the latest sequencing platforms by Pacific Biosciences (PacBio).
  • "We are excited to offer our Full-Length 16S Sequencing Service to the microbiome scientific community," said Marc Van Eden, PhD, VP of Business Development at Zymo Research.
  • In addition to launching its Full-Length 16S Sequencing Service, Zymo Research has become one of PacBio's preferred certified service providers.

MGI Empowers the Completion of Nearly 60,000 Samples for The Million Microbiome of Humans Project

Retrieved on: 
월요일, 5월 15, 2023
University College London, Karolinska Institute, DNA, Disease, University, Partnership, Institute of technology, Food, COVID-19, INRAE, Research, Biomedical Research, DNB, USD, De novo, Organization, Inborn errors of metabolism, United Nations Research Institute for Social Development, Technical University of Denmark, Cancer, Medicine, Copenhagen, University of Copenhagen Faculty of Health and Medical Sciences, Ecology, Health, Metagenomics, Microbiology, MGI, Virulence, Fine chemical, Pharmaceutical industry, Antibiotics, Environment

Despite a brief interruption by the COVID-19 pandemic, we are delighted to see such a monumental milestone merely four years into the project."

Key Points: 
  • Despite a brief interruption by the COVID-19 pandemic, we are delighted to see such a monumental milestone merely four years into the project."
  • Advances in genome sequencing has enabled researchers to better characterize the composition of the microbiome through identification of unculturable microbes.
  • Besides human microbiome, it is highly applicable in agricultural microbiome studies, environmental microbiome studies, pathogen surveillance and identification, and monitoring of antimicrobial resistance genes.
  • MGISP-960's fully automatic operation design allows DNA extraction of 50,000 samples per year and library preparation of 25,000 samples per year.

Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

Retrieved on: 
월요일, 5월 8, 2023
Metagenomics, Drug discovery, Boehringer Ingelheim, Database, DNA, Partnership, Acquisition, Ginkgo Bioworks, Ginkgo, NYSE, Disease, Patient, Pharmaceutical industry, Fine chemical, Zymergen, Codebase

BOSTON, May 8, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim.

Key Points: 
  • BOSTON, May 8, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim.
  • Hundreds of millions of people are living with diseases that to date cannot be cured or are inadequately treated.
  • "Ginkgo is well-positioned to help partners like Boehringer Ingelheim complement their drug discovery efforts particularly when it comes to natural product discovery," said Jason Kelly, CEO and co-founder at Ginkgo Bioworks.
  • "We are thrilled to work with Boehringer Ingelheim leveraging our Foundry and Codebase to unlock new possibilities in biopharma innovation."